Search

Your search keyword '"ANNOVAZZI, P"' showing total 78 results

Search Constraints

Start Over You searched for: Author "ANNOVAZZI, P" Remove constraint Author: "ANNOVAZZI, P" Database OpenAIRE Remove constraint Database: OpenAIRE
78 results on '"ANNOVAZZI, P"'

Search Results

1. Signs and symptoms of COVID-19 in patients with multiple sclerosis

2. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

3. Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

4. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

5. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases

7. Comparative effectiveness of dimethyl fumarate, teriflunomide, interferon-beta and glatiramer acetate on newly diagnosed patients: a propensity score-matched analysis from a multicenter Italian group

10. Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis

11. Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis

13. The diagnosis of multiple sclerosis: pinpointing the concept of 'no better explanation'

14. Comorbidities affect treatment choice and persistence in RRMS: a real-life multicenter study

15. To switch therapies in RRMS: why and when? A real-life multicentre study

16. Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis

17. Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients

28. Genetic burden of common variants in progressive and bout-onset multiple sclerosis

29. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of an Italian cohort of 462 cases

30. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience

34. Pregnancy does not prevent disease re-activation after natalizumab suspension in patients with multiple sclerosis

36. The diagnosis of multiple sclerosis: pinpointing the concept of 'no better explanation'

38. Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis

39. Comparative effectiveness of Cladribine tablets vs other drugs in relapsing-remitting multiple sclerosis: an approach merging randomized controlled trial with real life data

40. Shift from fingolimod to alemtuzumab: what happens next?

41. T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment

42. Comorbidities affect treatment choice and persistence in RRMS: a multicenter study

44. A real-world study of Alemtuzumab in a cohort of Italian patients

45. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study

46. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

47. Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail

48. Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study

49. Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group

50. A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia

Catalog

Books, media, physical & digital resources